{"protocolSection":{"identificationModule":{"nctId":"NCT02927301","orgStudyIdInfo":{"id":"ML39236"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)","officialTitle":"A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-05-07","type":"ACTUAL"},"completionDateStruct":{"date":"2023-09-05","type":"ACTUAL"},"studyFirstSubmitDate":"2016-10-05","studyFirstSubmitQcDate":"2016-10-05","studyFirstPostDateStruct":{"date":"2016-10-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-04-23","resultsFirstSubmitQcDate":"2021-04-23","resultsFirstPostDateStruct":{"date":"2021-05-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-08-16","lastUpdatePostDateStruct":{"date":"2024-09-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":181,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atezolizumab","type":"EXPERIMENTAL","description":"Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","description":"Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.","armGroupLabels":["Atezolizumab"],"otherNames":["RO5541267, MPDL3280A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Major Pathologic Response (MPR)","description":"Major pathologic response was defined as ≤10% of viable tumor cells as scored by a pathologist, based on surgical resection as defined by prior studies. Percentages have been rounded off to the nearest decimal point.","timeFrame":"After surgery (approximately 10 weeks)"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for PD-L1-Positive Versus PD-L1-Negative Participants","description":"ORR was defined as percentage of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST v.1.1, assessed in the programmed death ligand 1 (PD-L1) positive (participants with combined tumor cell (TC)/ immune cell (IC) score categorized as TC1/2/3 or IC1/2/3) and PD-L1 negative (participants with TC/IC score was categorized as TC0 and IC0) groups. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \\<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Percentages have been rounded off to the nearest decimal point.","timeFrame":"Pre-surgery (Day 36 +/- 3 days), after 2 doses of neoadjuvant treatment with atezolizumab"},{"measure":"Percentage of Participants With Major Pathologic Response for PD-L1-Positive Versus PD-L1-Negative Participants","description":"Major pathologic response (MPR) was defined as ≤10% of viable tumor cells, as scored by a pathologist, based on surgical resection as defined by prior studies. MPR was assessed based on participants tumor cell (TC) and immune cell (IC) score. The participants were considered as PD-L1- positive if their combined TC/IC score was categorized as TC1/2/3 or IC1/2/3 and the participants were considered PD-L1 negative if TC/IC score was categorized as TC0 and IC0. Percentages have been rounded off to the nearest decimal point.","timeFrame":"After surgery (approximately 10 weeks)"},{"measure":"Number of Participants With at Least One Adverse Event","description":"An adverse event (AE) was defined as any untoward medical occurrence in participant administered a pharmaceutical product \\& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \\& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).","timeFrame":"From first study dose of atezolizumab until 90 days after the last study dose of atezolizumab (up to 18 months)"},{"measure":"Percentage of Participants With Major Pathologic Response (MPR) by Mutation Load","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. Whole-exome sequencing (WES) was run, and the consequences of each mutation were determined using Ensembl Variant Effect Predictor (VEP). Mutation load (i.e. tumor mutation burden (TMB)) was defined as the number of variants altering protein sequence as outlined by VEP divided by 34 Megabase (MB) of assay target region. The final value was reported as number of mutations per megabase (mut/MB). It was divided into three groups: TMB \\<10 mut/MB; TMB ≥ 10 mut/MB to \\<16 mut/MB; and TMB ≥16 mut/MB. Percentages have been rounded off to the nearest decimal point.","timeFrame":"Up to 13 weeks"},{"measure":"Percentage of Participants With Major Pathologic Response (MPR) by Neoantigen Score","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by neoantigen score, which was assessed based on the number of highly immunogenic, expressed neoantigens detected at baseline. Median splits were applied for analyses of MPR. Neoantigen scores \\>/= 73 (i.e. \\>/= 73 highly immunogenic, expressed neoantigens detected at baseline) were considered as high scores, and scores \\<73 (i.e. \\<73 highly immunogenic, expressed neoantigens detected at baseline) were considered as low neoantigen scores. Percentages have been rounded off to the nearest decimal point.","timeFrame":"Up to 13 weeks"},{"measure":"Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: Gene Set Variation Analysis (GSVA)","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by gene set variation analysis (GSVA) scores. Bulk ribonucleic acid (RNA) from baseline tumor samples were assessed using GSVA for a T effector cell (Teff) signature comprising the following genes: cluster of differentiation 8A (CD8A), eomesodermin (EOMES), granzyme A (GZMA), T-box transcription factor 21 (TBX21), interferon-gamma (IFNG), granzyme B (GZMB), C-X-C motif chemokine ligand 9 (CXCL9), and C-X-C motif chemokine ligand 10 (CXCL10). Tertile splits were applied to GSVA scores, categorized as lower, middle, and upper scores, which indicated the relative levels of gene set expression in the baseline tumor samples. Percentages have been rounded off to the nearest decimal point.","timeFrame":"Up to 13 weeks"},{"measure":"Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: xCell Immune Score","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by gene expression signatures. Bulk RNA from baseline tumor samples were assessed using xCell immune score. Tertile splits were applied to xCell immune scores, categorized as lower, middle, and upper scores, which indicated the relative levels of immune cell gene expression in the baseline tumor samples. Percentages have been rounded off to the nearest decimal point.","timeFrame":"Up to 13 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC\n* Adequate pulmonary and cardiac function\n* Available biopsy of primary tumor with adequate samples\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease\n* Any prior therapy for lung cancer within 3 years.\n* Prior treatment with anti-PD-1 or PD-L1 therapies\n* History or risk of autoimmune disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"City of Hope Comprehensive Cancer Center","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"UCLA Cancer Center","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"University Of Colorado","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Yale Cancer Center","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Moffitt Cancer Center","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Emory University; Winship Cancer Institute","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Dana Farber Cancer Institute; Brigham and Womens Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Mass General/North Shore Cancer","city":"Danvers","state":"Massachusetts","zip":"01923","country":"United States","geoPoint":{"lat":42.57509,"lon":-70.93005}},{"facility":"Karmanos Cancer Inst; Hematology/Oncology","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Washington University; Wash Uni. Sch. Of Med","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Dartmouth Hitchcock Medical Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"Memorial Sloan Kettering - Monmouth","city":"Middletown","state":"New Jersey","zip":"07748","country":"United States","geoPoint":{"lat":40.39428,"lon":-74.11709}},{"facility":"Memorial Sloan Kettering Cancer Center - Commack","city":"Commack","state":"New York","zip":"11725","country":"United States","geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Memorial Sloan Kettering Cancer Center at Westchester","city":"Harrison","state":"New York","zip":"10604","country":"United States","geoPoint":{"lat":40.96899,"lon":-73.71263}},{"facility":"New York University Medical Center","city":"New York","state":"New York","zip":"10036","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering - Basking Ridge","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Nassau","city":"Uniondale","state":"New York","zip":"11553","country":"United States","geoPoint":{"lat":40.70038,"lon":-73.59291}},{"facility":"The Ohio State University Comprehensive Cancer Center","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}}]},"referencesModule":{"references":[{"pmid":"36097216","type":"DERIVED","citation":"Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 Oct;28(10):2155-2161. doi: 10.1038/s41591-022-01962-5. Epub 2022 Sep 12."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 181 participants diagnosed with Stage IB, II, IIIA, or selected IIIB resectable and untreated non-small-cell lung cancer (NSCLC) took part in the study in the United States from 20 Apr 2017 to 05 Sep 2023.","groups":[{"id":"FG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 milligram (mg) as intravenous (IV) infusion, once every 21 days (Q21D) for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"181"}]},{"type":"Participants Who Had Surgery","achievements":[{"groupId":"FG000","numSubjects":"159"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"115"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"66"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"39"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"}]},{"type":"Study Ended By Sponsor While in Survival Follow-Up","reasons":[{"groupId":"FG000","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all enrolled participants who have received any dose of study drug.","groups":[{"id":"BG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"181"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.1","spread":"9.23"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"93"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"88"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"159"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"14"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"145"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"14"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Major Pathologic Response (MPR)","description":"Major pathologic response was defined as ≤10% of viable tumor cells as scored by a pathologist, based on surgical resection as defined by prior studies. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The Primary Efficacy Population (PEP) included NSCLC participants who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have Epidermal Growth Factor Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) mutant tumors. The overall number analyzed was the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"After surgery (approximately 10 weeks)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"binomial test","paramType":"Other/Percentage","paramValue":"20.3","ciPctValue":"95","ciNumSides":"ONE_SIDED","ciLowerLimit":"14.900"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for PD-L1-Positive Versus PD-L1-Negative Participants","description":"ORR was defined as percentage of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST v.1.1, assessed in the programmed death ligand 1 (PD-L1) positive (participants with combined tumor cell (TC)/ immune cell (IC) score categorized as TC1/2/3 or IC1/2/3) and PD-L1 negative (participants with TC/IC score was categorized as TC0 and IC0) groups. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \\<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analyzed included participants in the PEP with non-missing ORR data and PD-L1 status. The PEP included participants with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row was the number of participants with data available for analysis in each PD-L1 group.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-surgery (Day 36 +/- 3 days), after 2 doses of neoadjuvant treatment with atezolizumab","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"}]}],"classes":[{"title":"PD-L1 Positive Group","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"5.9","upperLimit":"24.6"}]}]},{"title":"PD-L1 Negative Group","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.1","upperLimit":"10.3"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0358","statisticalMethod":"Fisher Exact","paramType":"Risk Difference (RD)","paramValue":"11.410","ciPctValue":"80","ciNumSides":"ONE_SIDED","ciLowerLimit":"5.279"}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Pathologic Response for PD-L1-Positive Versus PD-L1-Negative Participants","description":"Major pathologic response (MPR) was defined as ≤10% of viable tumor cells, as scored by a pathologist, based on surgical resection as defined by prior studies. MPR was assessed based on participants tumor cell (TC) and immune cell (IC) score. The participants were considered as PD-L1- positive if their combined TC/IC score was categorized as TC1/2/3 or IC1/2/3 and the participants were considered PD-L1 negative if TC/IC score was categorized as TC0 and IC0. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analyzed included participants in the PEP with non-missing MPR data and PD-L1 status. PEP included participants with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row was the number of participants with data available for analysis in each PD-L1 group.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"After surgery (approximately 10 weeks)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"classes":[{"title":"PD-L1 Positive Group","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","lowerLimit":"18.4","upperLimit":"43.4"}]}]},{"title":"PD-L1 Negative Group","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0395","statisticalMethod":"Chi-squared","paramType":"Risk Difference (RD)","paramValue":"16.363","ciPctValue":"80","ciNumSides":"ONE_SIDED","ciLowerLimit":"6.509"}]},{"type":"SECONDARY","title":"Number of Participants With at Least One Adverse Event","description":"An adverse event (AE) was defined as any untoward medical occurrence in participant administered a pharmaceutical product \\& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \\& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).","populationDescription":"Safety population included all enrolled NSCLC participants who have received any dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first study dose of atezolizumab until 90 days after the last study dose of atezolizumab (up to 18 months)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Pathologic Response (MPR) by Mutation Load","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. Whole-exome sequencing (WES) was run, and the consequences of each mutation were determined using Ensembl Variant Effect Predictor (VEP). Mutation load (i.e. tumor mutation burden (TMB)) was defined as the number of variants altering protein sequence as outlined by VEP divided by 34 Megabase (MB) of assay target region. The final value was reported as number of mutations per megabase (mut/MB). It was divided into three groups: TMB \\<10 mut/MB; TMB ≥ 10 mut/MB to \\<16 mut/MB; and TMB ≥16 mut/MB. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analyzed included participants in the PEP with non-missing MPR and TMB data. The PEP included participants with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row is the number of participants with data available for analysis in each TMB subgroup.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 13 weeks","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"}]}],"classes":[{"title":"TMB <10 mut/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"8.3","upperLimit":"28.5"}]}]},{"title":"TMB ≥10 mut/MB to <16 mut/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"0.2","upperLimit":"41.3"}]}]},{"title":"TMB ≥16 mut/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"11.8","upperLimit":"61.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Pathologic Response (MPR) by Neoantigen Score","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by neoantigen score, which was assessed based on the number of highly immunogenic, expressed neoantigens detected at baseline. Median splits were applied for analyses of MPR. Neoantigen scores \\>/= 73 (i.e. \\>/= 73 highly immunogenic, expressed neoantigens detected at baseline) were considered as high scores, and scores \\<73 (i.e. \\<73 highly immunogenic, expressed neoantigens detected at baseline) were considered as low neoantigen scores. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analyzed included participants in the PEP with non-missing MPR and neoantigen score data. The PEP included those with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row is the number of participants with data available for analysis in each neoantigen score subgroup.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 13 weeks","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"title":"Low score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","lowerLimit":"7.5","upperLimit":"37.5"}]}]},{"title":"High score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","lowerLimit":"11.9","upperLimit":"44.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: Gene Set Variation Analysis (GSVA)","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by gene set variation analysis (GSVA) scores. Bulk ribonucleic acid (RNA) from baseline tumor samples were assessed using GSVA for a T effector cell (Teff) signature comprising the following genes: cluster of differentiation 8A (CD8A), eomesodermin (EOMES), granzyme A (GZMA), T-box transcription factor 21 (TBX21), interferon-gamma (IFNG), granzyme B (GZMB), C-X-C motif chemokine ligand 9 (CXCL9), and C-X-C motif chemokine ligand 10 (CXCL10). Tertile splits were applied to GSVA scores, categorized as lower, middle, and upper scores, which indicated the relative levels of gene set expression in the baseline tumor samples. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analysed included participants in the PEP with non-missing MPR and GSVA score data. The PEP included participants with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row was the number of participants with data available for analysis in each GSVA score subgroup.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 13 weeks","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"classes":[{"title":"Lower score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","lowerLimit":"3.8","upperLimit":"43.4"}]}]},{"title":"Middle score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","lowerLimit":"14.2","upperLimit":"61.7"}]}]},{"title":"Upper score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"13.3","upperLimit":"59.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: xCell Immune Score","description":"MPR was defined as ≤10% of viable tumor cells in the surgical resection as scored by a pathologist. MPR was analysed by gene expression signatures. Bulk RNA from baseline tumor samples were assessed using xCell immune score. Tertile splits were applied to xCell immune scores, categorized as lower, middle, and upper scores, which indicated the relative levels of immune cell gene expression in the baseline tumor samples. Percentages have been rounded off to the nearest decimal point.","populationDescription":"The overall number analyzed included participants in the PEP with non-missing MPR and xCell immune score data. The PEP included participants with NSCLC who had received surgery after neoadjuvant treatment with atezolizumab, received at least one dose of the study drug, and who did not have EGFR or ALK mutant tumors. The number analyzed per row was the number of participants with data available for analysis in each xCell immune score subgroup.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 13 weeks","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"classes":[{"title":"Lower score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","lowerLimit":"10.3","upperLimit":"56.0"}]}]},{"title":"Middle score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","lowerLimit":"6.8","upperLimit":"49.9"}]}]},{"title":"Upper score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"13.3","upperLimit":"59.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events: From first study dose of atezolizumab until 90 days after the last study dose of atezolizumab (up to 18 months); All-cause mortality: From first dose of study treatment until end of follow-up (up to 59 months)","description":"Safety population included all enrolled NSCLC participants who have received any dose of study drug.","eventGroups":[{"id":"EG000","title":"Atezolizumab","description":"Participants received atezolizumab, 1200 mg as IV infusion, Q21D for a maximum of 2 cycles (1 cycle=21 days) as neo-adjuvant therapy. Participants who demonstrated clinical benefit from neo-adjuvant therapy and subsequently underwent surgery then received adjuvant treatment with atezolizumab, 1200 mg, as IV infusion, Q21D for a maximum of 12 months.","deathsNumAffected":39,"deathsNumAtRisk":181,"seriousNumAffected":63,"seriousNumAtRisk":181,"otherNumAffected":168,"otherNumAtRisk":181}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":181}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":181}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":181}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":181}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":181}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Blood potassium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Tongue neoplasm malignant stage unspecified","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":181}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":181}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":181}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":181}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":181}]},{"term":"Pulmonary air leakage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":181}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":181}]},{"term":"Subcutaneous emphysema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Vocal cord dysfunction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":181}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Device leakage","organSystem":"Product Issues","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":181}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":39,"numAtRisk":181}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":32,"numAtRisk":181}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":40,"numAtRisk":181}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":18,"numAtRisk":181}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":181}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":181}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":181}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":54,"numAtRisk":181}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":181}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":181}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":181}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":38,"numAtRisk":181}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":181}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":181}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":181}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":33,"numAtRisk":181}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":181}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":181}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":181}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":181}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":29,"numAtRisk":181}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":181}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":181}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":181}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":36,"numAtRisk":181}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":41,"numAtRisk":181}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":181}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":181}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":181}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":181}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":181}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":181}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":181}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":26,"numAtRisk":181}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":15,"numAtRisk":181}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":181}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":181}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":181}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":93,"numAffected":79,"numAtRisk":181}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":181}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":181}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":181}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":25,"numAtRisk":181}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":181}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":181}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Genentech","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-02-15","uploadDate":"2024-08-16T10:22","filename":"Prot_002.pdf","size":2299170},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-06-16","uploadDate":"2024-08-16T10:22","filename":"SAP_003.pdf","size":5597191}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"}]}},"hasResults":true}